Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

224 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.
Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Fisher RI. Stiff PJ, et al. Among authors: unger jm. N Engl J Med. 2013 Oct 31;369(18):1681-90. doi: 10.1056/NEJMoa1301077. N Engl J Med. 2013. PMID: 24171516 Free PMC article. Clinical Trial.
Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.
Fisher RI, Dana BW, LeBlanc M, Kjeldsberg C, Forman JD, Unger JM, Balcerzak SP, Gaynor ER, Roy V, Miller T. Fisher RI, et al. Among authors: unger jm. J Clin Oncol. 2000 May;18(10):2010-6. doi: 10.1200/JCO.2000.18.10.2010. J Clin Oncol. 2000. PMID: 10811664 Clinical Trial.
Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study.
Gaynor ER, Unger JM, Miller TP, Grogan TM, White LA Jr, Mills GM, Balcerzak SP, Varterasian M, LeBlanc M, Fisher RI. Gaynor ER, et al. Among authors: unger jm. J Clin Oncol. 2001 Feb 1;19(3):750-5. doi: 10.1200/JCO.2001.19.3.750. J Clin Oncol. 2001. PMID: 11157027 Clinical Trial.
Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease.
Press OW, LeBlanc M, Lichter AS, Grogan TM, Unger JM, Wasserman TH, Gaynor ER, Peterson BA, Miller TP, Fisher RI. Press OW, et al. Among authors: unger jm. J Clin Oncol. 2001 Nov 15;19(22):4238-44. doi: 10.1200/JCO.2001.19.22.4238. J Clin Oncol. 2001. PMID: 11709567 Clinical Trial.
A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy--Southwest Oncology Group study.
Whitehead RP, Unger JM, Flaherty LE, Kraut EH, Mills GM, Klein CE, Chapman RA, Doolittle GC, Hammond N, Sondak VK; Southwest Oncology Group. Whitehead RP, et al. Among authors: unger jm. Invest New Drugs. 2002 Feb;20(1):105-11. doi: 10.1023/a:1014484821460. Invest New Drugs. 2002. PMID: 12003185 Free article. Clinical Trial.
A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.
Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, Fisher RI. Press OW, et al. Among authors: unger jm. Blood. 2003 Sep 1;102(5):1606-12. doi: 10.1182/blood-2003-01-0287. Epub 2003 May 8. Blood. 2003. PMID: 12738671 Free article. Clinical Trial.
The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial.
Stiff PJ, Unger JM, Forman SJ, McCall AR, LeBlanc M, Nademanee AP, Bolwell BJ, Fisher RI; Southwest Oncology Group. Stiff PJ, et al. Among authors: unger jm. Biol Blood Marrow Transplant. 2003 Aug;9(8):529-39. doi: 10.1016/s1083-8791(03)00205-2. Biol Blood Marrow Transplant. 2003. PMID: 12931122 Free article. Clinical Trial.
Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project.
Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel RM, Weisenberger DD, Chan WC, Muller-Hermelink HK, Jaffe ES, Gascoyne RD, Campo E, Fuchs DA, Spier CM, Fisher RI, Delabie J, Rosenwald A, Staudt LM, Grogan TM. Rimsza LM, et al. Among authors: unger jm. Blood. 2004 Jun 1;103(11):4251-8. doi: 10.1182/blood-2003-07-2365. Epub 2004 Feb 19. Blood. 2004. PMID: 14976040 Free article.
224 results